Director/PDMR Shareholding | 13-Mar-2024 | 15:48 | RNS |
Board Committee Change | 08-Mar-2024 | 17:12 | RNS |
GSK announces positive Blenrep DREAMM-8 results | 07-Mar-2024 | 07:00 | RNS |
ViiV LAI vs oral SOC data in adherence-challenged | 06-Mar-2024 | 16:00 | RNS |
GSK Annual Report 2023 on Form 20-F | 05-Mar-2024 | 17:24 | RNS |
New ViiV LA formulation potential 4-month dosing | 05-Mar-2024 | 07:00 | RNS |
Total Voting Rights | 01-Mar-2024 | 15:00 | RNS |
GSK publishes Annual Report 2023 | 01-Mar-2024 | 12:15 | RNS |
Directorate Change | 29-Feb-2024 | 07:05 | RNS |
Statement: Zantac (ranitidine) litigation | 29-Feb-2024 | 07:00 | RNS |
Director/PDMR Shareholding | 26-Feb-2024 | 15:30 | RNS |
GSK announces positive EAGLE-1 headline results | 26-Feb-2024 | 07:00 | RNS |
Director/PDMR Shareholding | 22-Feb-2024 | 15:30 | RNS |
ViiV LAI superior to orals in adherence-challenged | 21-Feb-2024 | 07:00 | RNS |
Julie Brown - External Appointment | 20-Feb-2024 | 09:01 | RNS |
Currency | UK Pounds |
Share Price | 1,653.00p |
Change Today | 12.50p |
% Change | 0.76 % |
52 Week High | 1,711.20 |
52 Week Low | 1,316.00 |
Volume | 3,273,134 |
Shares Issued | 4,144.88m |
Market Cap | £68,515m |
RiskGrade | 129 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 8 |
Buy | 5 |
Neutral | 9 |
Sell | 2 |
Strong Sell | 0 |
Total | 24 |
Latest | Previous | |
---|---|---|
Q4 | Q3 | |
Ex-Div | 22-Feb-24 | 16-Nov-23 |
Paid | 11-Apr-24 | 11-Jan-24 |
Amount | 16.00p | 14.00p |
Time | Volume / Share Price |
16:35 | 1,484,603 @ 1,653.00p |
16:35 | 3,000 @ 1,653.00p |
16:35 | 3,859 @ 1,653.00p |
16:35 | 219 @ 1,653.00p |
16:35 | 454 @ 1,653.00p |
You are here: research